Drug subsidiaries. Background and practical rules
Kampmann, J.P.
Ugeskrift for Laeger 151(50): 3418-3420
1989
ISSN/ISBN: 0041-5782 PMID: 2609458 Document Number: 345118
Document emailed within 1 workday
Related Documents
Chazard, E.; Ficheur, Gégoire.; Merlin, Béatrice.; Serrot, E.; Beuscart, Régis. 2009: Adverse drug events prevention rules: multi-site evaluation of rules from various sources Studies in Health Technology and Informatics 148: 102-111Gardner, E. 1991: HBO streamlining operations of two subsidiaries; 130 jobs cut Modern Healthcare 21(27): 10
Vozeh, S. 1984: Drug level determination for optimization of drug therapy. Practical significance and new trends Schweizerische Rundschau für Medizin Praxis 73(49): 1505-1506
Andersson, K. 1998: There are rules on drug prescription Lakartidningen 95(18): 2062
De Groot, H.; van Herten, J. 2006: The new veterinary drug agreement and the new veterinary drug rules 2005: what does that mean for your practice? Tijdschrift Voor Diergeneeskunde 131(1): 14-17
Palva, E. 1999: Rules of the game in drug marketing Duodecim; Laaketieteellinen Aikakauskirja 115(20): 2187; 2189
Ladee, G.A. 1972: Background and risks of drug use Nederlands Tijdschrift Voor Geneeskunde 116(28): 1192-1193
Fox, T.C.; Robinson, C.L. 1990: Establishing procedures to implement drug therapy rules Provider 16(10): 65-66
Fong, T. 2004: Rules and regulations. CMS addresses drug prices, payment rates Modern Healthcare 34(31): 8-9 13
Rooseniit, R. 1970: Secret rules no hindrance for physicians to register young drug addicts Lakartidningen 67(30): 3356-3359
Takizawa, Y.; Wada, Y.; Horita, M.; Kitazawa, S.; Futamata, H.; Hashimoto, T. 1994: Quantitative analysis of EEG background activity in drug-naive schizophrenic patients Rinsho Byori. Japanese Journal of Clinical Pathology 42(7): 759-763
Despotou, G.; Korkontzelos, I.; Matragkas, N.; Bilici, E.; Arvanitis, T.N. 2018: Structuring Clinical Decision Support Rules for Drug Safety Using Natural Language Processing Studies in Health Technology and Informatics 251: 89-92
Băceanu, A.; Atasiei, Iţ.; Chazard, E.; Leroy, N. 2009: The expert explorer: a tool for hospital data visualization and adverse drug event rules validation Studies in Health Technology and Informatics 148: 85-94
Apley, M.D. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Practical aspects of flexible labeling in feedlots Journal of the American Veterinary Medical Association 207(7): 901
Volf, K.; Pitr, K.; Ryjácek, Z. 1992: Practical experience in the use of HPTLC for drug screening Soudni Lekarstvi 37(1): 5-9
Sharma, D.C. 2004: India pressed to relax rules on clinical trials. Drug companies claim changes are essential, but critics fear Indian patients will become guinea pigs Lancet 363(9420): 1528-1529
Vas, A.; Gachályi, B.; Káldor, A. 1987: Simultaneous microsomal monooxygenase enzyme system induction and inhibition, and the influence of the pharmacogenetic background: potential hazards in multi-drug therapy? International Journal of Clinical Pharmacology Therapy and Toxicology 25(7): 410
Begaud, B.; Haramburu, F.; Père, J.C.; Dangoumau, J. 1982: Practical considerations in attributing drug effects: 1 000 cases Therapie 37(4): 415-420
Saw, S.M.; Lim, S.G. 2000: Clinical drug trials: practical problems of phase III Annals of the Academy of Medicine Singapore 29(5): 598-605
Tucker, G.T.; Jackson, P.R.; Lennard, M.S.; Woods, H.F. 1986: The detection of polymorphic drug oxidation--some theoretical and practical aspects Progress in Clinical and Biological Research 214: 413-424